Stock 512 GRAND PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Grand Pharmaceutical Group Limited

Equities

512

BMG210A71016

Delayed Hong Kong S.E.
Other stock markets
 23:12:33 2024-05-15 EDT 		5-day change 1st Jan Change
5.12 HKD +2.61% Intraday chart for Grand Pharmaceutical Group Limited +2.62% +24.69%
04-29 Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump MT
03-27 Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan
Grand Pharmaceutical Unit Enrolls, Doses 1st Patient in Sepsis Drug Phase 2 Trial
Grand Pharma Gets China's Nod for Phase 1 Clinical Trial for Tumor Vaccine
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 512 Stock
  4. News Grand Pharmaceutical Group Limited
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW